The C-Met library offered by contains 16,000 compounds that target the c-MET receptor tyrosine kinase. This receptor plays a crucial role in regulating cell processes such as proliferation, survival, motility, differentiation, and morphogenesis, and its dysregulation has been implicated in the development and progression of several types of cancer.
Most of the compounds in development target the c-MET receptor either through ATP-competitive or non-competitive inhibition. While ATP-competitive inhibitors tend to be potent, they are less specific and can inhibit other kinases. In contrast, non-competitive inhibitors may be more specific because they do not target the ATP pocket and instead interact with allosteric sites of the receptor. This results in changes in the conformation of the active site, which alters the binding of the ligand HGF.
One example of an ATP-competitive drug that inhibits MET and exhibits antitumor activity is cabozantinib.
C-Met library provides a valuable resource for researchers seeking to identify novel compounds that can target the c-MET receptor and potentially lead to the development of effective therapies for cancer.
